Endotoxin-Free
E. coli-Free
Precision-Engineered
High-purity HMOs, sustainable salidroside, and bio-active marine peptides. Manufactured for Morika Bio via our proprietary yeast synthesis platform -- eliminating the endotoxin risks of legacy bacterial systems.
Morika Bio Global Quality Unit -- Certifications & Compliance
Technical Resource Center
The Product Pillars
Three precision-engineered bio-active platforms, produced under our BioSync™ 3rd-Gen Precision Yeast Synthesis technology. Manufactured for Morika Bio.
BioSync™ Platform
Human Milk Oligosaccharides
- Endotoxin-Free & E. coli-Free
- pH 6.7 | Moisture < 0.2%
- First FDA GRAS for LNTr II
CITES-Compliant
Bio-Fermented Salidroside
- 100% CITES-Compliant
- Zero Heavy Metal Contamination
- Sustainable Yeast Synthesis
Enzymatic Hydrolysis
Marine Peptides 37°N
- High-Activity Enzyme Extraction
- Standardized Low MW
- 37°N Premium Sea Cucumber
Application Segments
Precision-Engineered for Every Vertical
Our BioSync™ bio-active portfolio serves four key verticals across global nutrition, wellness, and clinical skincare. Manufactured for Morika Bio.
Infant Nutrition
BioSync™ HMO-enriched formulations mimicking the protective properties of breast milk. Endotoxin-free, E. coli-free. First FDA GRAS globally for LNTr II.
Adult Gut Health
Precision prebiotics targeting the gut microbiome for enhanced digestive wellness and immune support. 99.9% purity via BioSync™ yeast synthesis.
Sports & Performance
BioSync™ salidroside for enhanced endurance and reduced fatigue. 98% pure, 100% CITES-compliant, zero heavy metal contamination.
Clinical Skincare
Transdermal-grade marine peptides (<1000 Da) from the 37°N ecological zone for clinically validated skin recovery and rejuvenation.
Since 2015
Our Innovation Milestones
A decade of advancing precision fermentation, regulatory milestones, and global market access for next-generation bio-actives.
Foundation
Established R&D partnership for precision fermentation of bio-active compounds.
Foundation
Established R&D partnership for precision fermentation of bio-active compounds.
BioSync™ Platform Launch
Deployed 1st-generation yeast synthesis for salidroside production. Achieved 95% purity benchmark.
BioSync™ Platform Launch
Deployed 1st-generation yeast synthesis for salidroside production. Achieved 95% purity benchmark.
HMO Production Scale-Up
Scaled BioSync™ to produce 2'-FL and LNT at commercial volumes. Zero endotoxin validated.
HMO Production Scale-Up
Scaled BioSync™ to produce 2'-FL and LNT at commercial volumes. Zero endotoxin validated.
FDA GRAS Milestones
Received FDA GRAS no-objection for 2'-FL and LNT. First globally for LNTr II via yeast synthesis.
FDA GRAS Milestones
Received FDA GRAS no-objection for 2'-FL and LNT. First globally for LNTr II via yeast synthesis.
37°N Marine Peptides Launch
Launched high-activity enzymatic extraction from premium 37°N ecological zone sea cucumbers.
37°N Marine Peptides Launch
Launched high-activity enzymatic extraction from premium 37°N ecological zone sea cucumbers.
Global Expansion
FSSC 22000 certification. EU Novel Food authorization. Shanghai APAC headquarters established.
Global Expansion
FSSC 22000 certification. EU Novel Food authorization. Shanghai APAC headquarters established.
3rd-Gen BioSync™
BioSync™ 3rd-Gen platform achieves 99.9% HMO purity. CITES-compliant salidroside at 98% purity.
3rd-Gen BioSync™
BioSync™ 3rd-Gen platform achieves 99.9% HMO purity. CITES-compliant salidroside at 98% purity.
Morika Bio Global Quality Unit
Led by a Global Ph.D. Team with 30+ Years of Expertise
Our production chain holds 110+ global patents in biosynthesis. We take full legal and technical ownership of product quality before global distribution through our internal Morika Bio Global Quality Unit.
BioSync™ platform eliminates endotoxin risks inherent in legacy E. coli-based fermentation systems.
Global Patents in Biosynthesis
Years of Enzyme Engineering
Countries Served